←
Chris Kosmidis670 posts
Chris Kosmidis avatar

Chris Kosmidis

@ckosmidis

Infectious Diseases Physician and Researcher, University of Manchester. Interested in all aspergillosis clinical syndromes, invasive, allergic and chronic.

◷ Joined May 2009▧ 22 Photos and videos
British Society for Medical Mycology avatar
⟳ Chris Kosmidis retweeted
British Society for Medical Mycology@BritSocMedMyc·Nov 11

🍄 Interested in a PhD in medical mycology? At our recent Glasgow meeting, Prof. Tihana Bicanic shared details of the exciting new Mycology Doctoral Training Programme (MYCO-DTP). Find out more about this fantastic opportunity here: mycodtp.org/ #medicalmycology

MRC Centre for Medical Mycology avatar
⟳ Chris Kosmidis retweeted
MRC Centre for Medical Mycology@MRCcmm·Oct 29

Interested in a PhD in medical mycology? Applications are now open for the MycoDTP training programme! 🧫 Deadline for applications: 4th December 2026 Find out more and apply mycodtp.org/

NEJM avatar
⟳ Chris Kosmidis retweeted
NEJM@NEJM·Sep 16

In a randomized trial involving adults who received local antibiotics during surgery for orthopedic infection, a short duration of systemic antibiotics was noninferior to a long duration regarding treatment failure at 12 months. Full SOLARIO trial results: nej.md/4dgrqwY

Post attachment
National Aspergillosis Centre avatar
⟳ Chris Kosmidis retweeted
National Aspergillosis Centre@MFT_NAC·Sep 3

Chronic aspergillosis sometimes occurs alongside other long-term lung conditions and infections If you are affected by NTM (non-tuberculous Mycobacterium) and/or bronchiectasis, you can find out more with this online event aimed at patients and their families

Join @NJHealth on Sept 19, 2026, for the NTM & Bronchiectasis Patient & Family Course! Learn disease management and treatment advances. Register: bit.ly/45UnIoX #ntmawareness #bronchiectasis #lunghealth

Post attachment
Paul Sax avatar
⟳ Chris Kosmidis retweeted
Paul Sax@PaulSaxMD·Aug 18

Congratulations to the @remap_cap investigators for conducting this important clinical trial, which will undoubtedly change clinical practice and treatment guidelines (or at least it should). Free link in first reply. @NEJM

Post attachment
Martin Hoenigl🇺🇦🇦🇹 avatar
⟳ Chris Kosmidis retweeted
Martin Hoenigl🇺🇦🇦🇹@martinhoenigl·Apr 27

Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients - businesswire.com/news/home/2…

James D Chalmers avatar
⟳ Chris Kosmidis retweeted
James D Chalmers@ProfJDChalmers·Mar 7

UCB therapeutics announces they will trial anti-IL17/IL-13 multispecific antibody therapy in bronchiectasis in 2026 The pipeline of new therapies coming into the bronchiectasis and COPD field is exciting to see and will ultimately be great for patients. ucb.com/newsroom/press-relea…

Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 avatar
⟳ Chris Kosmidis retweeted
Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟@ABsteward·Mar 7

🆕⚡🟢Pharmacokinetic and pharmacogenomic predictors of hepatotoxicity in the HIRIF trial for drug-susceptible tuberculosis Higher pyrazinamide and isoniazid exposures and slow NAT2 acetylator status were independently associated with hepatotoxicity. In multivariable analysis, only pyrazinamide exposure was associated with hepatotoxicity. Rifampicin exposure up to 20 mg/kg/day was not associated with hepatotoxicity, supporting its safe use. #idxposts academic.oup.com/cid/article…

National Aspergillosis Centre avatar
⟳ Chris Kosmidis retweeted
National Aspergillosis Centre@MFT_NAC·Feb 3

Today is #worldaspergillosisday - you can help by sharing this link with any GPs you know NAC worked with MIMS to produce this CPD course for learning about #aspergillosis to help CPA and #abpa be diagnosed and treated faster #respiratory #gps #pulmonary #respisbest

Aspergillus is a mould that is often seen in damp homes, and exposure can lead to #aspergillosis. This module, by specialists from the National Aspergillosis Centre (@MFT_NAC), looks at the diagnosis and management of the condition. buff.ly/rDAuxW9

Post attachment
Chris Kosmidis avatar
Chris Kosmidis@ckosmidis·Feb 2

Our new paper in Mycoses: Aspergillus serology predicts relapse in chronic pulmonary aspergillosis (#cpa). End-of-therapy ↑IgG and Aspergillus sensitisation predicted relapse. 👉 Towards personalised follow-up in CPA pubmed.ncbi.nlm.nih.gov/4161… @MFT_NAC @eurconfmedmycol